{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-016287","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.711001+00:00","generated_at":"2026-06-15T03:52:24.805343+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Dare Bioscience Q1 cash $19.8M; Sildenafil Cream Phase 2b data and XACIATO launch expected Q2","bullets":["Cash $19.8M at March 31; G&A $3.3M (up from $2.6M) on commercial-readiness and email fraud loss; R&D $5.0M (down from $5.8M).","Expects Sildenafil Cream Phase 2b topline data in Q2 2023 for FSAD, a condition with no FDA-approved treatments.","XACIATO first commercial sale by Organon expected Q2 2023, triggering $2.5M milestone payment to Daré.","Ovaprene pivotal Phase 3 contraceptive study start mid-2023 under NIH/NICHD CRADA; DARE-HRT1 and DARE-VVA1 IND prep ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-016287","json":"https://secwatch.observer/filing/0001493152-23-016287.json","markdown":"https://secwatch.observer/filing/0001493152-23-016287.md","text":"https://secwatch.observer/filing/0001493152-23-016287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/0001493152-23-016287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T03:52:24.805343+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6888818afe25be3486c09a59dc8bdbcf0933c810","claim":"Dare Bioscience, Inc. reported financial results for first fiscal quarter ended March 31, 2023.","evidence_excerpt":"Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223016287/0001493152-23-016287-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first fiscal quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}